Journal of Thrombosis and Haemostasis

Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients
pp. 731-735(5)
Authors: SOFI, F.; CESARI, F.; TU, Y.; PRATESI, G.; PULLI, R.; PRATESI, C.; GENSINI, G. F.; ABBATE, R.; BROZE JR, G. J.

New evidence on the potential role of the metabolic syndrome as a risk factor for venous thromboembolism
pp. 736-738(3)
Authors: AGENO, W.; DENTALI, F.; GRANDI, A. M.

Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study
pp. 739-745(7)
Authors: BORCH, K. H.; BRÆKKAN, S. K.; MATHIESEN, E. B.; NJØLSTAD, I.; WILSGAARD, T.; STØRMER, J.; HANSEN, J.-B.

Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology
pp. 746-751(6)
Authors: STEFFEN, L. M.; CUSHMAN, M.; PEACOCK, J. M.; HECKBERT, S. R.; JACOBS JR, D. R.; ROSAMOND, W. D.; FOLSOM, A. R.

Validation of a diagnostic approach to exclude recurrent venous thromboembolism
pp. 752-759(8)
Authors: LE GAL, G.; KOVACS, M. J.; CARRIER, M.; DO, K.; KAHN, S. R.; WELLS, P. S.; ANDERSON, D. A.; CHAGNON, I.; SOLYMOSS, S.; CROWTHER, M.; RIGHINI, M.; PERRIER, A.; WHITE, R. H.; VICKARS, L.; RODGER, M.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
pp. 760-765(6)
Authors: CARRIER, M.; LE GAL, G.; CHO, R.; TIERNEY, S.; RODGER, M.; LEE, A. Y.

The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis
pp. 766-773(8)
Authors: WILKE, T.; TESCH, S.; SCHOLZ, A.; KOHLMANN, T.; GREINACHER, A.

Major differences in bleeding symptoms between factor VII deficiency and hemophilia B
pp. 774-779(6)
Authors: BERNARDI, F.; DOLCE, A.; PINOTTI, M.; SHAPIRO, A. D.; SANTAGOSTINO, E.; PEYVANDI, F.; BATOROVA, A.; LAPECORELLA, M.; SCHVED, J. F.; INGERSLEV, J.; MARIANI, G.

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy
pp. 780-786(7)
Authors: SIBONI, S. M.; MANNUCCI, P. M.; GRINGERI, A.; FRANCHINI, M.; TAGLIAFERRI, A.; FERRETTI, M.; TRADATI, F. C.; SANTAGOSTINO, E.; von MACKENSEN, S.

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort
pp. 787-794(8)
Authors: COLLINS, P. W.; MATHIAS, M.; HANLEY, J.; KEELING, D.; KEENAN, R.; LAFFAN, M.; PERRY, D.; LIESNER, R.

Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial
pp. 795-802(8)
Authors: FENGER-ERIKSEN, C.; JENSEN, T. M.; KRISTENSEN, B. S.; JENSEN, K. M.; TØNNESEN, E.; INGERSLEV, J.; SØRENSEN, B.

Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin
pp. 803-810(8)
Authors: BAE, J.-S.; REZAIE, A. R.

Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A
pp. 811-824(14)
Authors: MADOIWA, S.; YAMAUCHI, T.; KOBAYASHI, E.; HAKAMATA, Y.; DOKAI, M.; MAKINO, N.; KASHIWAKURA, Y.; ISHIWATA, A.; OHMORI, T.; MIMURO, J.; SAKATA, Y.

Discordant fibrin formation in hemophilia
pp. 825-832(8)
Authors: BRUMMEL-ZIEDINS, K. E.; BRANDA, R. F.; BUTENAS, S.; MANN, K. G.

In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β₂-glycoprotein I: proof of concept
pp. 833-842(10)
Authors: IOANNOU, Y.; ROMAY-PENABAD, Z.; PERICLEOUS, C.; GILES, I.; PAPALARDO, E.; VARGAS, G.; SHILAGARD, T.; LATCHMAN, D. S.; ISENBERG, D. A.; RAHMAN, A.; PIERANGELI, S.

von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture
pp. 843-850(8)
Authors: LEROLLE, N.; DUNOIS-LARDé, C.; BADIROU, I.; MOTTO, D. G.; HILL, G.; BRUNEVAL, P.; DIEHL, J. -L.; DENIS, C. V.; BARUCH, D.

Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock
pp. 851-856(6)
Authors: XU, J.; JI, Y.; ZHANG, X.; DRAKE, M.; ESMON, C. T.

Optimization of a murine immunization model for study of PF4/heparin antibodies
pp. 857-864(8)
Authors: SUVARNA, S.; QI, R.; AREPALLY, G. M.

Abnormal platelet function in C3-deficient mice
pp. 865-870(6)
Authors: GUSHIKEN, F. C.; HAN, H.; LI, J.; RUMBAUT, R. E.; AFSHAR-KHARGHAN, V.

Regulation of cardiomyocyte full-length tissue factor expression and microparticle release under inflammatory conditions in vitro
pp. 871-878(8)
Authors: ANTONIAK, S.; BOLTZEN, U.; EISENREICH, A.; STELLBAUM, C.; POLLER, W.; SCHULTHEISS, H. P.; RAUCH, U.

Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization
pp. 879-883(5)
Authors: KAHN, S. R.; PARTSCH, H.; VEDANTHAM, S.; PRANDONI, P.; KEARON, C.

Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome
pp. 884-888(5)
Author: KAHN, S. R.

Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials
pp. 889-891(3)
Author: LASSEN, M. R.

Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general population
pp. 892-894(3)
Authors: GARCÍA RODRÍGUEZ, L. A.; PATRIGNANI, P.; GONZÁLEZ-PÉREZ, A.

Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay
pp. 894-897(4)
Authors: BOGDANOV, V. Y.; CIMMINO, G.; TARDOS, J. G.; TUNSTEAD, J. R.; BADIMON, J. J.

The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome
pp. 897-899(3)
Authors: KIM, I.-S.; CHOI, B.-R.; JEONG, Y.-H.; KWAK, C. H.; KIM, S.

CD9 negatively regulates integrin α_IIbβ₃ activation and could thus prevent excessive platelet recruitment at sites of vascular injury
pp. 900-902(3)
Authors: MANGIN, P. H.; KLEITZ, L.; BOUCHEIX, C.; GACHET, C.; LANZA, F.

High thrombin-activatable fibrinolysis inhibitor levels may protect against recurrent fetal loss
pp. 903-906(4)
Authors: KNOL, H. M.; VEEGER, N. J. G. M.; MIDDELDORP, S.; HAMULYÁK, K.; VAN DER MEER, J.

More on: high thrombin generation and the risk of recurrent venous thromboembolism
pp. 906-907(2)
Authors: TRIPODI, A.; LEGNANI, C.; PALARETI, G.; CHANTARANGKUL, V.; MANNUCCI, P. M.

Birger Blombäck (May 7, 1926 - October 2, 2008)
pp. 908-909(2)
Authors: LORD, S. T.; HENSCHEN-EDMAN, A.

Join ISTH
pp. 910-910(1)